RADX Radiopharm Theranostics Ltd


$ 5.20 $ -0.36 (-6.87 %)    

Monday, 03-Nov-2025 19:07:36 EST
QQQ $ 629.78 $ -3.11 (-0.49 %)
DIA $ 472.70 $ -2.66 (-0.56 %)
SPY $ 681.88 $ -2.29 (-0.33 %)
TLT $ 89.68 $ 0.07 (0.08 %)
GLD $ 366.72 $ 0.05 (0.01 %)
$ 4.88
$ 5.24
$ 4.85 x 100
$ 6.00 x 66
$ 4.85 - $ 5.24
$ 3.50 - $ 50.82
6,765
na
na
$ 0.68
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Preliminary data from first three patients in Phase 2b imaging clinical trial of RAD 101 show uptake in brain metastases from s...

Core News & Articles

Financial updateThe following is a summary of the Appendix 4C Cash Flow Report:The year-end closing cash balance was $29.12 mil...

Core News & Articles

- Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceu...

Core News & Articles

Radiopharm Theranostics (ASX: RAD, NASDAQ:RADX, &, ldquo, Radiopharm&, rdquo, or the &, ldquo, Company&, rdquo,...

Core News & Articles

Brookline Capital analyst Kemp Dolliver initiates coverage on Radiopharm Theranostics (NASDAQ:RADX) with a Buy rating and an...

Core News & Articles

RAD 402 preclinical data package complete; demonstrates safety and promising biodistribution profileEthics approval and Phase 1...

Core News & Articles

Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company fo...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION